Table 1 Characteristics of included studies.
From: Joining up the scattered anticancer knowledge on auraptene and umbelliprenin: a meta-analysis
Studies | Coumarin | Cancer | Cell line | Dose (µM) | Time (h) | Outcome * | Risk of bias ** |
|---|---|---|---|---|---|---|---|
Abolhassani et al. 2023 | AUR | Prostate | PC3 | 5–80 | 48 72 96 120 144 | treatment (n = 3): 1) 86.98 ± 6.82 2) 79.37 ± 5.52 3) 51.37 ± 5.33 control (n = 3): 84.7 ± 6.66 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Afshari et al. 2019 | AUR | Glioblastoma | U87 | 167–335 | 8 24 | treatment (n = 3): 6) 64.04 ± 3.05 7) 47.22 ± 3.11 control (n = 3): 100 ± 1.87 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Bagheri et al. 2022 | AUR | Leukemia/Lymphoma | MT-2 | 16.7–134 | 24 48 72 96 120 144 | treatment (n = 3): 2) 92.36 ± 5.07 3) 74.84 ± 5.57 control (n = 3): 95.96 ± 4.45 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Charmforoshan et al. 2019 | AUR | Breast | MCF-7 | 61–207 | 48 | treatment (n = 3): 3) 50 ± 3.65 4) 75 ± 4.79 7) 49.24 ± 2.52 control (n = 3): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦ Outcome: ♦♦ |
Epifano et al. 2013 | AUR | Colon | HT-29 HT-116 | 2.5–40 | 72 | treatment (n = 3): 1) 82.32 ± 10.88 2) 46.41 ± 10 control (n = 3): 99.81 ± 10.75 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Epifano et al. 2023 | AUR | Neuroblastoma | SHSY-5Y | 12.3–50 | 24 | treatment (n = 6): 2) 78.39 ± 5.82 3) 62.04 ± 5.81 control (n = 6): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦ Outcome: ♦♦ |
Gkionis et al. 2021 | AUR | Breast | MCF-7 MDA-MB231 | 1–100 | 48 | treatment (n = 2): 1) 97.43 ± 8.7 3) 56.97 ± 6.13 4) 26.11 ± 6.82 control (n = 2): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦ Outcome: ♦♦ |
Goudarzi et al. 2022 | AUR | Leukemia/Lymphoma | MT-2 | 10–40 | 48 72 96 | treatment (n = 3): 1) 92.54 ± 6.38 2) 87.64 ± 6.89 control (n = 3): 99.4 ± 1.76 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Izadi et al. 2023 | AUR | Glioblastoma | U87 | 40–330 | 24 | treatment (n = 3): 2) 89.38 ± 11.02 3) 80.81 ± 2.04 7) 46.53 ± 2.45 control (n = 3): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦ Outcome: ♦♦ |
Jalilzade et al. 2020 | AUR | Colon | HT-29 | 12.5–100 | 24 48 72 | treatment (n = 3): 2) 81.51 ± 3.42 3) 60.86 ± 3.47 4) 52.23 ± 3.22 control (n = 3): 99.91 ± 2.13 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Jamialahmadi et al. 2018 | AUR | Ovarian Cervical | A2780 HeLa | 3–100 | 24 | treatment (n = 3): 1) 86.12 ± 6.95 2) 63.56 ± 8.47 3) 51.96 ± 6.18 control (n = 3): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Krishnan et al. 2009 | AUR | Breast | MDA-MB231 MCF-7 | 1–50 | 24 | treatment (n = 3): 1) 95.41 ± 7.34 3) 34.67 ± 3.94 control (n = 3): 100 ± 6.19 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Lee et al. 2017 | AUR | Prostate | PC3 LNCaP DU145 | 15–120 | 24 | treatment (n = 3): 2) 79.91 ± 3.49 3) 63.39 ± 2.42 4) 49.73 ± 3.05 control (n = 3): 100 ± 2.8 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Li et al. 2013 | AUR | Breast | T47D MDA-MB231 | 1–30 | 48 144 | treatment (n = 3): 1) 87.19 ± 2.88 control (n = 3): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Moon et al. 2015 | AUR | Gastric | AGS MKN-45 SNU-1 SNU-16 | 12.5–100 | 48 | treatment (n = 3): 2) 84.26 ± 11.51 3) 48.53 ± 6.51 4) 37.89 ± 3.3 control (n = 3): 100 ± 5.31 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Movaffagh et al. 2023 | AUR | Gastric | MKN-45 | 16.7–133.6 | 24 48 72 96 120 | treatment (n = 3): 2) 84.32 ± 5.72 3) 65.43 ± 7.92 5) 43.63 ± 6.38 control (n = 3): 91.8 ± 3.5 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Shiran et al. 2021 | AUR | Breast | MDA-MB231 | 6.25–200 | 24 | treatment (n = 3): 1) 94.44 ± 2.96 2) 89.81 ± 2.41 3) 84.07 ± 2.59 4) 58.14 ± 2.6 control (n = 3): 100 ± 3.36 | Selection: ♦♦ Comparability: ♦♦♦ Outcome: ♦♦ |
Barthomeuf et al. 2008 | UMB | Colon Breast Ovarian Melanoma Prostate Lung | DLD1 MCF-7 PA1 M4Beu PC3 A549 | 27.3 | 48 | treatment (n = 3): 2) 45.24 ± 3.27 control (n = 3): 100 ± 2.29 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Gkionis et al. 2021 | UMB | Breast | MCF-7 MDA-MB231 | 1–100 | 48 | treatment (n = 2): 1) 96.98 ± 8.1 4) 46.93 ± 4.99 control (n = 2): 100 ± 2.29 | Selection: ♦♦ Comparability: ♦♦♦ Outcome: ♦♦ |
Goodarzi et al. 2022 | UMB | Leukemia/Lymphoma | MT-2 | 1–80 | 48 72 96 | treatment (n = 3): 3) 65.01 ± 7.06 control (n = 3): 99.36 ± 1.96 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Hamidinia et al. 2013 | UMB | Colon | SW48 | 6.25–200 | 24 48 72 | treatment (n = 3): 1) 90.83 ± 2.17 2) 83.22 ± 1.69 3) 67.03 ± 3.74 4) 42.4 ± 2.05 6) 11.66 ± 1.51 control (n = 3): 100 ± 2.29 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Kamalkazemi et al. 2023 | UMB | Colon | HT-29 | 20–140 | 24 48 | treatment (n = 3): 2) 64.34,1.95 3) 42.77 ± 1.28 4) 28.57 ± 1.46 5) 16.82 ± 1.88 control (n = 3): 100 ± 2.29 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Khaghanzadeh et al. 2012 | UMB | Lung | A549 QU-DB | 10–200 | 24 48 72 | treatment (n = 3): 1) 89.63 ± 2.57 2) 82 ± 4.15 3) 68.37 ± 4.73 4) 33.91 ± 7.72 6) 13 ± 3 control (n = 3): 94.16 ± 2.03 | Selection: ♦♦ Comparability: ♦♦♦♦♦♦ Outcome: ♦♦ |
Rashidi et al. 2016 | UMB | Colon Breast Glioma | HT-29 MCF-7 A172 | 8.1–272.8 | 24 48 72 | treatment (n = 3): 1) 98.88 ± 6.22 2) 84.7 ± 4.88 3) 64.43 ± 5.15 5) 36.6 ± 3.82 7) 16.85 ± 2.62 control (n = 3): 100 ± 2.29 | Selection: ♦♦ Comparability: ♦♦♦♦♦♦ Outcome: ♦♦ |
Zhang et al. 2019 | UMB | Gastric | AGS BGC-823 | 3.13–50 | 24 48 72 | treatment (n = 3): 1) 71.12 ± 3.44 2) 40.11 ± 3.98 3) 16.82 ± 2.92 control (n = 3): 99.63 ± 1.94 | Selection: ♦♦ Comparability: ♦♦♦♦♦ Outcome: ♦♦ |
Zhang et al. 2015 | UMB | Gastric Cervical Lung Prostate | AGS HeLa A549 PC3 | 6.25–121 | 24 | treatment (n = 3): 1) 87.72 ± 1.43 2) 67.43 ± 2.38 3) 49 ± 4.71 4) 35 ± 2.14 5) 50 + 2.28 control (n = 3): 1) 97.72 ± 1.72 2,3,4) 98.48 ± 1.72 5) 100 ± 1.72 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
Ziai et al. 2012 | UMB | Leukemia | Jurkat T | 10–100 | 16 48 | treatment (n = 3): 1) 80.83 ± 2.34 2) 68.25 ± 3.54 3) 44.38 ± 3 4) 26.72 ± 2.93 control (n = 3): 100 ± 2.29 | Selection: ♦♦ Comparability: ♦♦♦♦ Outcome: ♦♦ |
